13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases Download PDF Post navigationPreviousPrevious post:Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentNextNext post:AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSRelated PostsAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024Two financial analysis firms initiate coverage of AB ScienceMarch 6, 2024Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETMarch 1, 2024AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALSFebruary 26, 2024AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 26, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALSFebruary 26, 2024
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 26, 2024
